雷氏丹参片联合辛伐他汀治疗高胆固醇血症对肝功能的影响  

Effect of Danshen Tablet combined with Simvastatin on hepatic function in patients with hypercholesterolemia

作　　者：赵清[1] 赵炳辉[1] 魏盟[1] 

机构地区：[1]上海交通大学附属第六人民医院,上海200233

出　　处：《中成药》2009年第6期825-827,共3页Chinese Traditional Patent Medicine

摘　　要：目的:观察雷氏丹参片联合辛伐他汀治疗高胆固醇血症患者对肝功能的影响。方法:高胆固醇血症患者随机分为辛伐他汀组(n=20例)和雷氏丹参片联合辛伐他汀组(联合治疗组,n=20例),疗程3个月。治疗前后分别检测血脂(TC、TG、LDL-C、HDL-C)、AST、ALT和CPK。结果:两组血脂水平均较治疗前显著改善,且两组间无差异(P>0.05)。辛伐他汀组AST和ALT较治疗前有增高趋势,但无统计学差异(P>0.05);联合治疗组AST和ALT较治疗前有降低趋势,但无统计学差异(P>0.05),而两组间有差异(P<0.05)。两组及组间CPK无显著差异(P>0.05)。结论:雷氏丹参片联合辛伐他汀可降低降脂治疗对肝的损伤作用,具有保肝降酶,可作为临床上降脂治疗的辅助用药。AIM ： The present study is to observe the effect of Danshen Tablet combined with Simvastatin on hepatic function in patients with hypercholesterolemia. METHODS： Patients with hypercholesterolemia were randomly divided into Simvastatin treatment group （ n = 20） and Danshen Tablet combined with Simvastatin treatment group （n = 20）. Before study and after 12 weeks treatment, serum lipid （TC, TG, LDL-C, HDL-C, AST, ALT and CPK） were measured. RESULTS： After treatment, serum lipid in both groups were improved significantly, and there was no difference between them. In Simvastatin treatment group, there was a tendency to increase in ALT and AST, but we could reject at the significant level. In the same way, the serum lipid in combination treatment group decreased, but no statistic difference. Compared with Simvastatin treatment group, ALT and AST in combination treatment group reduced significantly. CPK in both groups did not change. CONCLUSION： Danshen Tablet can reduce liver injury by statin and could serve as an adjuvant in clinical hypolipidemic treatment.

关 键 词：雷氏丹参片 辛伐他汀 高胆固醇血症 肝脏 

分 类 号：R287[医药卫生—中药学]